Bionano Genomics
Preliminary Earnings Roundup: Oxford Nanopore, 10x Genomics, Bionano Genomics, Standard BioTools
Several tools firms reported fourth quarter and full-year 2024 revenues and other business updates ahead of the annual JP Morgan Healthcare Conference this week.
Bionano Genomics Restructures Debt, Initiates $10M Direct Offering
The optical genome mapping firm deferred its December 2024 amortization payment and reduced payments in the first half of 2025 to improve its cash position, and separately announced a $10 million direct stock offering.
Bionano Genomics' Chinese Partner Nabs NMPA Approval for Saphyr OGM Platform
With the approval, Bionano's OEM partner Hangzhou Diagens Biotechnology can now sell the platform directly to hospitals and clinical labs in China.
In Brief This Week: Myriad Genetics, Europa Biosite, Mount Sinai, DeepUll, Thermo Fisher, More
News items for the weeks of Nov. 25 and Dec. 2, 2024.
Bionano Genomics Shifts Focus to Existing Users, Plans Further Layoffs as Q3 Revenues Fall Short
Premium
Strapped for cash, the optical genome mapping company's Q3 revenues declined 34 percent year over year, falling below the Wall Street consensus estimate.
May 28, 2024
Bionano Genomics Raises $17.9M in Debt Financing
May 8, 2024
Bionano Genomics Q1 Revenues up 18 Percent
Jan 17, 2024
Nov 8, 2023